Stock Market News
Pfizer. BioNTech seek to revoke CureVac’s patent infringement claims
2022.09.02 16:50
A vial labelled “CureVac COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
(Reuters) – Pfizer (NYSE:PFE) and its German partner BioNTech have filed proceedings at the High Court of England & Wales seeking judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday.